HomeBUSINESS
BUSINESS

Global Sales of Shionogi’s Novel Influenza Drug Could Reach US$1 Billion: President
(Nov.1.2017)

Shionogi President Isao Teshirogi suggested on October 30 that sales of the influenza treatment S-033188, which has been granted sakigake fast-track designation, will be affected by the results of an ongoing PIII clinical trial in individuals at high risk for influenza-related complications. If the trial, dubbed CAPSTONE-2, is successful and expands the range of patients eligible to use the drug, its global sales could eventually reach US$1 billion, Dr Teshirogi predicted ...
(LOG IN FOR FULL STORY)

News Calendar